BACKGROUND: Mu opioid receptor (OPRM1) ligands may alter expression of chemokines and chemokine receptors involved in penetration of human immunodeficiency virus (HIV) type 1 into the cell. We suggest that OPRM1 variants may affect the pathophysiology of HIV infection. METHODS: DNA samples from 1031 eligible African Americans, Hispanics, and whites from the Women's Interagency HIV Study (WIHS) who were alive as of April 2006 were analyzed. We performed regression analysis of association of 18 OPRM1 variants with a change of viral load and CD4 cell count during 2 periods: between admission to WIHS and the start of highly active antiretroviral therapy (HAART) (interval X) and between the start of HAART and the most recent WIHS visit (interval Y), and examined the association of these variants with HIV status. RESULTS: Regardless of genotype, a significant decrease in viral load during interval X was found for each ethnicity. Whites with allele G of the functional polymorphism 118A > G (reference sequence rs1799971) showed a smaller decrease in viral load; those bearing minor alleles IVS1 + 1050A, IVS1 + 14123A, and IVS2 + 31A showed a larger decrease in viral load over interval X (0.01 < P < .05). Hispanics with the same alleles showed a greater increase in CD4 cell count over interval Y (0.01 < P < .05). We found an association between OPRM1 variants and HIV status in African Americans and whites. CONCLUSIONS: OPRM1 polymorphisms may alter the severity of HIV infection before and after HAART.
BACKGROUND: Mu opioid receptor (OPRM1) ligands may alter expression of chemokines and chemokine receptors involved in penetration of human immunodeficiency virus (HIV) type 1 into the cell. We suggest that OPRM1 variants may affect the pathophysiology of HIV infection. METHODS: DNA samples from 1031 eligible African Americans, Hispanics, and whites from the Women's Interagency HIV Study (WIHS) who were alive as of April 2006 were analyzed. We performed regression analysis of association of 18 OPRM1 variants with a change of viral load and CD4 cell count during 2 periods: between admission to WIHS and the start of highly active antiretroviral therapy (HAART) (interval X) and between the start of HAART and the most recent WIHS visit (interval Y), and examined the association of these variants with HIV status. RESULTS: Regardless of genotype, a significant decrease in viral load during interval X was found for each ethnicity. Whites with allele G of the functional polymorphism 118A > G (reference sequence rs1799971) showed a smaller decrease in viral load; those bearing minor alleles IVS1 + 1050A, IVS1 + 14123A, and IVS2 + 31A showed a larger decrease in viral load over interval X (0.01 < P < .05). Hispanics with the same alleles showed a greater increase in CD4 cell count over interval Y (0.01 < P < .05). We found an association between OPRM1 variants and HIV status in African Americans and whites. CONCLUSIONS: OPRM1 polymorphisms may alter the severity of HIV infection before and after HAART.
Authors: Gavin Bart; K Steven LaForge; Lisa Borg; Charles Lilly; Ann Ho; Mary Jeanne Kreek Journal: Neuropsychopharmacology Date: 2006-06-21 Impact factor: 7.853
Authors: I P Keet; J Tang; M R Klein; S LeBlanc; C Enger; C Rivers; R J Apple; D Mann; J J Goedert; F Miedema; R A Kaslow Journal: J Infect Dis Date: 1999-08 Impact factor: 5.226
Authors: D C Des Jarlais; S R Friedman; D M Novick; J L Sotheran; P Thomas; S R Yancovitz; D Mildvan; J Weber; M J Kreek; R Maslansky Journal: JAMA Date: 1989-02-17 Impact factor: 56.272
Authors: T E Wilson; L S Massad; K A Riester; S Barkan; J Richardson; M Young; A Gurtman; R Greenblatt Journal: AIDS Date: 1999-04-01 Impact factor: 4.177
Authors: Elizabeth Ducat; Brenda Ray; Gavin Bart; Yoshie Umemura; Jack Varon; Ann Ho; Mary Jeanne Kreek Journal: Addict Biol Date: 2011-04-20 Impact factor: 4.280
Authors: C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu Journal: Proc Natl Acad Sci U S A Date: 1998-08-04 Impact factor: 11.205
Authors: Seth M Dever; Blair N Costin; Ruqiang Xu; Nazira El-Hage; Joyce Balinang; Alexander Samoshkin; Megan A O'Brien; Marypeace McRae; Luda Diatchenko; Pamela E Knapp; Kurt F Hauser Journal: AIDS Date: 2014-01-02 Impact factor: 4.177
Authors: Sylvia Fitting; Krista L Scoggins; Ruqiang Xu; Seth M Dever; Pamela E Knapp; William L Dewey; Kurt F Hauser Journal: Eur J Pharmacol Date: 2012-05-30 Impact factor: 4.432
Authors: Nazira El-Hage; Seth M Dever; Elizabeth M Podhaizer; Christopher K Arnatt; Yan Zhang; Kurt F Hauser Journal: AIDS Date: 2013-09-10 Impact factor: 4.177